Stockscreener 앱 받기
28.01
5.54%
1.47
시장 영업 전:
28.06
0.05
+0.18%
전일 마감가:
$26.54
열려 있는:
$27.66
하루 거래량:
763.71K
Relative Volume:
0.16
시가총액:
$20.80B
수익:
$956.00K
순이익/손실:
$-221.32M
주가수익비율:
-87.53
EPS:
-0.32
순현금흐름:
$-142.25M
1주 성능:
-0.92%
1개월 성능:
+37.37%
6개월 성능:
+13.63%
1년 성능:
+177.60%
1일 변동 폭
$27.59
$28.15
1주일 범위
$25.81
$28.61
52주 변동 폭
$8.88
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
명칭
Summit Therapeutics Inc
전화
305-203-2034
주소
601 BRICKELL KEY DRIVE, MIAMI
SMMT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
28.01 | 19.71B | 956.00K | -221.32M | -142.25M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-01 | 개시 | UBS | Buy |
| 2025-06-11 | 개시 | Leerink Partners | Underperform |
| 2025-03-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-03-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-12 | 개시 | Evercore ISI | Outperform |
| 2025-02-28 | 개시 | Goldman | Buy |
| 2025-01-08 | 개시 | Truist | Buy |
| 2024-12-11 | 개시 | Wells Fargo | Overweight |
| 2024-12-06 | 개시 | Jefferies | Buy |
| 2024-11-04 | 개시 | JMP Securities | Mkt Outperform |
| 2024-09-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-08-12 | 개시 | H.C. Wainwright | Buy |
| 2024-05-07 | 개시 | Citigroup | Buy |
| 2024-03-26 | 개시 | Stifel | Buy |
| 2018-06-28 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-05-02 | 개시 | Janney | Buy |
| 2018-04-12 | 재확인 | Needham | Buy |
| 2018-02-13 | 개시 | BTIG Research | Buy |
| 2018-01-04 | 개시 | SunTrust | Buy |
| 2017-12-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-10-05 | 재확인 | Needham | Buy |
| 2016-09-16 | 개시 | H.C. Wainwright | Buy |
| 2015-03-30 | 개시 | Needham | Buy |
| 2015-03-30 | 개시 | Oppenheimer | Outperform |
모두보기
Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스
Is Summit Therapeutics Inc. a good long term investmentHigh-octane financial growth - Autocar Professional
Meet the Biotech Stock That Rocketed 775% Higher - AOL.com
What drives Summit Therapeutics Inc. stock priceTremendous growth potential - Autocar Professional
What analysts say about Summit Therapeutics Inc. stockExplosive capital appreciation - jammulinksnews.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Summit Therapeutics Inc. (SMMT) And Encourages Investors to Connect - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.SMMT - PR Newswire
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results - The Motley Fool
Bronstein, Gewirtz & Grossman, LLC Encourages Summit Therapeutics Inc. (SMMT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
This Healthcare Stock's Revolutionary Drug Could Make Early Investors Rich - Yahoo Finance
3 Monster Stocks in the Making to Buy Right Now - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Summit Therapeutics Inc. (SMMT) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Trading (SMMT) With Integrated Risk Controls - news.stocktradersdaily.com
Summit Therapeutics PLC (NASDAQ:SMMT) Shares Acquired by Cerity Partners LLC - Defense World
Summit Therapeutics Inc. Stock Analysis and ForecastFree Predictions - Autocar Professional
Published on: 2025-07-19 02:49:19 - jammulinksnews.com
Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Summit Therapeutics Inc. (SMMT) And Encourages Investors to Reach Out - ACCESS Newswire
Principal Financial Group Inc. Has $4.75 Million Stock Holdings in Summit Therapeutics PLC (NASDAQ:SMMT) - Defense World
Summit Therapeutics: Not Entirely Positive HARMONi Data And Partnership Rumors (SMMT) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Summit Therapeutics Inc. (SMMT) And Encourages Stockholders to Reach Out - ACCESS Newswire
This Biotech Stock Jumped Over 600% in Just Days After Releasing Promising Clinical Trial Data. And Its Market Cap Is Still Only $2 Billion. But Is It a Buy? - AOL.com
10 Stocks Exploding Higher: Bitcoin Miners Dominate the List - Insider Monkey
how summit therapeutics inc. stock performs during market volatilityAnalyst Grade Signals - Newser
Summit Therapeutics Jumps 16% On Heavy Volume As Technicals Signal Bullish Breakout - AInvest
Summit Therapeutics Inc (SMMT) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Summit Therapeutics Explodes 12%: Legal Probe Ignites Volatility Amid Regulatory Crosshairs - AInvest
Summit Therapeutics Soars 16.5% Amid Regulatory Crossroads and Whale Activity - AInvest
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug - MSN
What makes Summit Therapeutics Inc. stock price move sharplyFree Predictions - Newser
H.C. Wainwright Keeps Their Buy Rating on Summit Therapeutics (SMMT) - The Globe and Mail
Why Summit Therapeutics Inc. stock attracts strong analyst attentionFree Trading Group - Newser
Revolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid Tumors - MSN
SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm - Business Wire
BPAS - FinancialContent
Summit Therapeutics (SMMT) Rated Buy on Ivonescimab’s Cancer-Fighting Potential - MSN
Summit Therapeutics (SMMT) Jumps 7.6% on Reports of $15-Billion AstraZeneca Deal - MSN
Where are the Opportunities in (SMMT) - news.stocktradersdaily.com
10 Stocks Going Wild - Insider Monkey
Summit Therapeutics Inc (SMMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.51%
0.25%
자본화:
|
볼륨(24시간):